Novel Materials In Devices May Require Additional Biocompatibility Testing
This article was originally published in The Gray Sheet
FDA reviewers ask manufacturers to put novel materials in devices through additional testing beyond what is described in existing guidance documents.
You may also be interested in...
An FDA device reviewer and an agency toxicologist talk to The Gray Sheet about key industry considerations for biocompatibility testing, emphasizing a growing focus on testing absorbable implants and testing for allergens in devices.
Upcoming workshop will help manufacturers understand when they should submit a new 510(k) for changes to an existing product. CDRH plans to extend early feasibility pilot until May 2014. More regulatory news.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.